Spero Therapeutics Inc(SPRO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:38 PM ET (Korea 10/29 05:38)
Full metrics table
| Index | - | P/E | 10.71 | EPS (ttm) | 0.11 | Insider Own | 26.19% | Shs Outstand | 58.1M | Perf Week | - |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | 4.12% | Insider Trans | -0.17% | Shs Float | 43.0M | Perf Month | -2.5% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.47 | Inst Own | 15.56% | Short Float | 1.96% | Perf Quarter | -2.5% |
| Income | 0.01B | P/S | 1.59 | EPS this Y | -746.67% | Inst Trans | 1.65% | Short Ratio | 1.31 | Perf Half Y | -53.75% |
| Sales | 0.04B | P/B | 1.54 | EPS next 5Y | - | ROA | 12.85% | Short Interest | 0.84M | Perf YTD | -49.79% |
| Book/sh | 0.76 | P/C | 1.34 | EPS past 3/5Y | - | ROE | 19.17% | 52W High | -62.01% ($3.08) | Perf Year | -50.84% |
| Cash/sh | 0.87 | P/FCF | 3.48 | Sales past 3/5Y | 7.06% 197% | ROIC | 16.69% | 52W Low | 12.5% ($1.04) | Perf 3Y | 14.71% |
| Dividend Est. | - | EV/EBITDA | 7.52 | EPS Y/Y TTM | 114.38% | Gross Margin | - | Volatility(W/M) | 5.06% 5.8% | Perf 5Y | -93.33% |
| Dividend TTM | - | EV/Sales | 0.45 | Sales Y/Y TTM | 26.04% | Oper. Margin | 6% | ATR (14) | 0.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.12 | EPS Q/Q | -443.89% | Profit Margin | 17.18% | RSI (14) | 50.64 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.12 | Sales Q/Q | -100% | SMA20 | 1.21% ($1.16) | Beta | 1.57 | Target Price | $6 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/8/12 | SMA50 | -0.86% ($1.18) | Rel Volume | 0.53 | Prev Close | $1.14 |
| Employees | 25 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -41.41% ($2) | Avg Volume(3M) | 0.64M | Price | $1.17 |
| IPO | 2017/11/2 | Option/Short | Yes/Yes | Trades | 637 | Volume | 337,840 | Change | 2.63% |
Spero Therapeutics is a US-based, clinical-stage biopharmaceutical company developing novel antibiotics to combat multi-drug-resistant infectious diseases. Its portfolio includes oral carbapenem-class antibiotics and other candidate compounds targeting gram-negative and non-tuberculous mycobacterial (NTM) infections. Through collaborations with major pharmaceutical companies, the company is expanding its pipeline in the antibacterial field, where there is significant unmet medical need.
Over the past 1 year, on the lower side
62% below its 1-year high.
Traded less than usual. That is 53% of its average volume.
SPRO makes money exceptionally well
Of every $100 in sales, $6.00 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -746.7% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $752. Peers typically go for $2,136. It is about in line with its own 2-year average.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -93.3%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 15.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #393 of 594 in the industry
Based on market cap of $68M.
TENX#390 Tenax Therapeutics Inc $70M PER - 
CRDF#391 Cardiff Oncology Inc $70M PER - 
CSBR#392 Champions Oncology Inc $68M PER - SPRO#393 Spero Therapeutics Inc $68M PER 10.7 
FBIO#394 Fortress Biotech Inc $65M PER 0.7 
FAQ
What kind of company is SPRO?
SPRO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SPRO?
The market cap of SPRO is approximately $68M, ranking 4,703 within its sector.
What is the P/E ratio of SPRO?
SPRO has a P/E ratio of approximately 10.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for SPRO?
SPRO has recorded a 52-week high of $3.08 and a low of $1.04.
